QUICK POLL
If imatinib, nilotinib, and dasatinib are all approved for front-line therapy of newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML), what would you recommend as front-line therapy for a 42-year-old man who presents with high-risk CML by both the Sokal and Hasford (Euro) scoring systems and who has no matched sibling donor?

Exploring the Spectrum of Immunomodulatory Therapy
in Hematologic Malignancies
A Satellite Symposium at Lymphoma & Myeloma 2008: An International Congress on Hematologic Malignancies
Friday, October 17, 2008
New York, New York
Waldorf=Astoria
Friday, October 17, 2008
11:15 am
Assembly and Lunch
11:35 am
Introductions & opening remarks
Ruben Niesvizky, MD
11:40 am
Exploring the mechanisms of activity of IMiD® compounds
Asher A. Chanan-Khan, MD
11:55 am
Q&A
12:00 am
Evolution in the therapeutic landscape for multiple myeloma
Jeffrey A. Zonder, MD
12:15 pm
Q&A
12:20 pm
Emerging novel therapies for aggressive non-Hodgkin’s lymphomas
Paul A. Hamlin, MD
12:35 pm
Q&A
12:40 pm
Expanding the therapeutic options in CLL
Asher A. Chanan-Khan, MD
12:55 pm
Q&A
1:00 pm
Adjourn


